NCOG-19. BEVACIZUMAB IN REAL LIFE PATIENTS WITH RECURRENT GLIOBLASTOMA: BENEFIT OR FUTILITY?

Angiogenesis represents a hallmark of glioblastoma but most trials disappointed and failed to change the poor outcome of this disease. However, Bevacizumab (Bev) is widely used in clinical practice by expert oncologists due to experience or efficacy in real life.We retrospectively reviewed the use o...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Smolenschi, Cristina, Colomba, Emeline, Rassy, Elie, Lezghed, Naima, Kettab, Mohamed, Louvel, Guillaume, Garcia, Gabriel, Cheaib, Bianca, Bockel, Sophie, Pallud, Johan, Dezamis, Edouard, Copaciu, Razvan, Knafo, Steven, Ammari, Samy, Dhermain, Frederic, Domont, Julien, Martanovschi, Larisa, Mahmoud, Fekih, Dumont, Sarah
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2020
Gaiak:
Outcome Measures and Neuro-Cognitive Outcomes
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7651623/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noaa215.558
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak